plasma kallikrein Inhibitors

The chemical class of plasma kallikrein inhibitors consists of various compounds that primarily influence the coagulation cascade and related inflammatory processes. These inhibitors function either by directly targeting proteases within the cascade or by modulating the overall coagulation and inflammation pathways, thereby indirectly affecting plasma kallikrein. Compounds such as Ecallantide, Aprotinin, and Conestat alfa act by directly inhibiting proteases. Ecallantide is a specific inhibitor of kallikrein, thus directly reducing its activity in coagulation and kinin generation. Aprotinin, a broad-spectrum serine protease inhibitor, can inhibit kallikrein among other proteases, affecting both coagulation and inflammatory processes. Conestat alfa, a recombinant C1 inhibitor, affects the complement system, which is closely linked to kallikrein activity. Other inhibitors in this class, including Tranexamic Acid, Berinert, Icatibant, Danaparoid, Fondaparinux, Dalteparin, Enoxaparin, and Warfarin, exert their effects through various mechanisms within the coagulation pathway. Tranexamic Acid inhibits plasminogen activation, a process related to fibrinolysis where kallikrein is involved. Icatibant, as a bradykinin receptor antagonist, modulates the effects downstream of kallikrein activation. Low molecular weight heparins like Dalteparin and Enoxaparin, as well as anticoagulants like Fondaparinux and Warfarin, indirectly influence the coagulation factors and pathways involving kallikrein.